SAB Biotherapeutics annual total assets
2020
2021
2022
2023
2024
2025
SAB Biotherapeutics Total Assets Growth & History (SABS)
SAB Biotherapeutics's total assets was $172.8M for fiscal 2025.
View full SAB Biotherapeutics company overviewSAB Biotherapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $172.8M | $128.6M | +291.01% |
| 2024 | 2024-12-31 | $44.2M | −$39.7M | −47.35% |
| 2023 | 2023-12-31 | $83.9M | $33.0M | +64.90% |
| 2022 | 2022-12-31 | $50.9M | −$30.2M | −37.26% |
| 2021 | 2021-12-31 | $81.1M | $24.6M | +43.52% |
| 2020 | 2020-12-31 | $56.5M | — | — |
SAB Biotherapeutics quarterly total assets
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $238.2M | $208.1M | +690.62% |
| Q1 2026 | 2026-03-31 | $248.5M | $210.4M | +551.81% |
| Q4 2025 | 2025-12-31 | $172.8M | $128.6M | +291.01% |
| Q3 2025 | 2025-09-30 | $183.4M | $129.7M | +241.00% |
| Q2 2025 | 2025-06-30 | $30.1M | −$31.8M | −51.32% |
| Q1 2025 | 2025-03-31 | $38.1M | −$33.3M | −46.59% |
| Q4 2024 | 2024-12-31 | $44.2M | −$39.7M | −47.35% |
| Q3 2024 | 2024-09-30 | $53.8M | $25.5M | +89.85% |
| Q2 2024 | 2024-06-30 | $61.9M | $26.4M | +74.63% |
| Q1 2024 | 2024-03-31 | $71.4M | $28.7M | +67.26% |
| Q4 2023 | 2023-12-31 | $83.9M | $33.0M | +64.90% |
| Q3 2023 | 2023-09-30 | $28.3M | −$24.2M | −46.03% |
| Q2 2023 | 2023-06-30 | $35.4M | −$24.0M | −40.34% |
| Q1 2023 | 2023-03-31 | $42.7M | −$25.8M | −37.69% |
| Q4 2022 | 2022-12-31 | $50.9M | −$30.2M | −37.26% |
| Q3 2022 | 2022-09-30 | $52.5M | −$64.4M | −55.09% |
| Q2 2022 | 2022-06-30 | $59.4M | −$57.7M | −49.26% |
| Q1 2022 | 2022-03-31 | $68.5M | −$48.8M | −41.60% |
| Q4 2021 | 2021-12-31 | $81.1M | — | — |
| Q3 2021 | 2021-09-30 | $116.9M | — | — |
| Q2 2021 | 2021-06-30 | $117.1M | — | — |
| Q1 2021 | 2021-03-31 | $117.3M | — | — |
SAB Biotherapeutics total assets trends
Over the last five fiscal years, SAB Biotherapeutics's total assets increased from $56.5M to $172.8M, a change of $116.3M. The latest reported quarter, Q2 2026, shows $238.2M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SAB Biotherapeutics source filings ↗